<SEC-DOCUMENT>0001144204-12-040241.txt : 20120720
<SEC-HEADER>0001144204-12-040241.hdr.sgml : 20120720
<ACCEPTANCE-DATETIME>20120719210523
ACCESSION NUMBER:		0001144204-12-040241
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120719
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120720
DATE AS OF CHANGE:		20120719

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0101

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		12970859

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v319090_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;SECURITIES AND EXCHANGE COMMISSION&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section&nbsp;13 or 15(d) of
the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; width: 33%">Date of Report (Date of Earliest Event Reported):</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; width: 33%">July 19, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt">STAAR Surgical
Company<BR>
</FONT><FONT STYLE="font-size: 10pt">__________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 33%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 33%; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: underline; text-align: center; padding: 0; text-indent: 0"><U>Delaware</U></TD>
    <TD STYLE="text-decoration: underline; text-align: center; padding: 0; text-indent: 0"><U>0-11634</U></TD>
    <TD STYLE="text-decoration: underline; text-align: center; padding: 0; text-indent: 0"><U>95-3797439</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">(State or other jurisdiction</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">(Commission</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">(I.R.S. Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">of incorporation)</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">File Number)</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">Identification No.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: underline; text-align: center; padding: 0; text-indent: 0"><U>1911 Walker Ave, Monrovia, California</U></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-decoration: underline; text-align: center; padding: 0; text-indent: 0"><U>91016</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">(Address of principal executive offices)</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 10%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 44%; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">Registrant&rsquo;s telephone number, including area code:</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">626-303-7902</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Not Applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Former name or former address, if changed
since last report</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.4pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-weight: bold; text-indent: 0; width: 10%">Item 2.02</TD>
    <TD STYLE="padding: 0; font-weight: bold; text-indent: 0; width: 90%">Results of Operations and Financial Condition</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 63pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 63pt">On July 19, 2012, STAAR Surgical Company
issued a Press Release providing its selected preliminary financial results for the second quarter ended June 29, 2012. A copy
of the Press Release is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 63pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 63pt">The financial information furnished in this Current Report
for the quarter ended June 29, 2012 is selected preliminary information and remains subject to review by STAAR Surgical Company&rsquo;s
independent registered public accountants. STAAR Surgical Company will release its financial results for the quarter on August
1, 2012. Financial information for the quarter, which STAAR Surgical Company will release on August 1, 2012 or report in its Quarterly
Report on Form 10-Q, may differ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 63pt">The information furnished herewith
pursuant to Item&nbsp;2.02 of this Current Report, including Exhibit 99.1, shall not be deemed to be &ldquo;filed&rdquo; for the
purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject
to the liabilities of that section. The information in this Current Report shall not be incorporated by reference into any filing
under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report,
regardless of any general incorporation language in the filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-weight: bold; text-indent: 0; width: 10%">Item 9.01</TD>
    <TD STYLE="padding: 0; font-weight: bold; text-indent: 0; width: 90%">Financial Statements and Exhibits</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; padding: 0; font-weight: bold; text-decoration: underline; text-indent: 0">Exhibit No.</TD>
    <TD STYLE="width: 90%; padding: 0; font-weight: bold; text-decoration: underline; text-indent: 0">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">99.1</TD>
    <TD STYLE="padding: 0; text-indent: 0">Press Release, dated July 19, 2012, of STAAR Surgical Company.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 0; text-indent: 0">STAAR Surgical Company&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; padding: 0; text-indent: 0">July 19, 2012</TD>
    <TD STYLE="width: 3%; padding: 0; text-indent: 0">By:</TD>
    <TD STYLE="width: 82%; text-decoration: underline; padding: 0; text-indent: 0"><U>/s/ Barry G. Caldwell</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Barry G. Caldwell</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">President and Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 97%; padding: 0; font-weight: bold; text-indent: 0">Exhibit Index</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-weight: bold; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">99.1</TD>
    <TD STYLE="padding: 0; text-indent: 0">Press Release, dated July 19, 2012, of STAAR Surgical Company.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v319090_ex99-1.htm
<DESCRIPTION>EXHIBIGT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>STAAR SURGICAL PROVIDES OUTLOOK ON SECOND
QUARTER 2012 FINANCIAL RESULTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>Second Quarter Revenue of Approximately
$16 Million</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>Cash Position Increases to a Record
$17.5 Million</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>Full Second Quarter 2012 Results to
be Announced on August 1</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MONROVIA, CA, July 19, 2012 -- STAAR Surgical Company (NASDAQ:
STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today provided selected preliminary
results for the second quarter ended June 29, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Total revenue is expected to be approximately $16 million compared
with $16.3 million in the second quarter of 2011 and $15.5 million in the first quarter of 2012. Visian ICL sales increased in
all three regions though at a less than anticipated level in Asia Pacific and Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;During the quarter, the transition to a direct selling
model for our Visian ICL in Spain had a negative impact on our sales, though it will provide an upside to expectations in Spain
during the second half of the year. The negative sales impact came from the lack of re-orders from the market as the distributor
worked down its inventory and STAAR incurred additional reduction in sales as we bought back the remainder of the inventory during
the quarter. In Asia Pacific we had lower than expected sales in Korea, our largest market, and China. These were partially offset
by strong increases in Japan, Germany, Italy, India and Latin America. North America grew within expectations during the quarter,&rdquo;
said Barry Caldwell, President and CEO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;In addition, based on preliminary review of our second
quarter results, we expect our cash position increased to approximately $17.5 million at quarter end, which is a record cash position
for the Company and was achieved while we made continued investments in our future,&rdquo; added Mr. Caldwell. &ldquo;We have now
hired thirteen of the budgeted sixteen new employees in the sales and marketing area and expect to see enhanced results during
the second half of 2012 from these additions. We also invested approximately $700,000 in our manufacturing consolidation project
during the quarter. The project is running ahead of schedule and is expected to help drive our gross margins to nearly 80% and
reduce our current tax rate of 50% to 10% beginning in 2014.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company will release its financial results for the second
quarter ended June 29, 2012 on Wednesday, August 1, 2012 after the market close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Conference Call Information</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STAAR Surgical will host a conference call and webcast on Wednesday,
August 1, 2012 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its second quarter 2012 results and recent corporate developments.
The dial-in number for the conference call is 800-762-8779 for domestic participants and 480-629-9645 for international participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company will also be using slides to illustrate its second
quarter results and operational progress. The slides and live webcast of the call can be accessed from the investor relations section
of the STAAR website at www.staar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>About STAAR Surgical</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STAAR, which has been dedicated solely to ophthalmic surgery
for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye. All of these lenses are foldable,
which permits the surgeon to insert them through a small incision. STAAR&rsquo;s lens used in refractive surgery as an alternative
to LASIK is called an Implantable Collamer&reg; Lens or &ldquo;ICL.&rdquo; A lens used to replace the natural lens after cataract
surgery is called an intraocular lens or &ldquo;IOL.&rdquo; Over 300,000 Visian ICLs have been implanted to date; to learn more
about the ICL go to: www.visianinfo.com. STAAR has approximately 300 full time employees and markets lenses in approximately 50
countries. Headquartered in Monrovia, CA, it manufactures in the following locations: Nidau, Switzerland; Ichikawa City, Japan;
Aliso Viejo, CA; and Monrovia, CA. For more information, please visit the Company&rsquo;s website at <U>www.staar.com</U> or call
626-303-7902.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Collamer&reg; is the registered trademark for STAAR&rsquo;s
proprietary biocompatible collagen copolymer lens material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Safe Harbor</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All statements in this press release that are not statements
of historical fact are forward-looking statements, including statements about any of the following: any projections of earnings,
revenue, sales, profit margins, cash or any other financial items; the plans, strategies, and objectives of management for future
operations or prospects for achieving such plans; prospects for increased sales as a result of new product introductions or new
product approvals, expected savings from business consolidation plans and the timetable for those plans; the approval of pending
regulatory applications; statements of belief; and any statements of assumptions underlying any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These statements are based on expectations and assumptions as
of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ
materially from those described in the forward-looking statements. The risks and uncertainties include the following: our limited
capital resources and limited access to financing; the negative effect of poor global economic conditions on sales of products,
especially products such as the ICL used in non-reimbursed elective procedures; the challenge of managing our foreign subsidiaries;
backlog as we ramp up production to meet rapidly growing demand for our products; the risk of unfavorable changes in currency exchange
rate; the discretion of regulatory agencies to approve or reject new products, or to require additional actions before approval;
unexpected costs or delays that could reduce or eliminate the expected benefits of our consolidation plans; the risk that research
and development efforts will not be successful or may be delayed in delivering for launch; the willingness of surgeons and patients
to adopt a new product and procedure; patterns of Visian ICL use that have typically limited our penetration of the refractive
surgery market, and a general decline in the demand for refractive surgery particularly in the U.S., which STAAR believes has resulted
from both concerns about the safety and effectiveness of laser procedures and current economic conditions. The Visian Toric ICL
and the V4c are not yet approved for sale in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; padding: 0; text-indent: 0">CONTACT:</TD>
    <TD STYLE="width: 5%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 30%; padding: 0; text-indent: 0">Investors</TD>
    <TD STYLE="width: 2%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 48%; padding: 0; text-indent: 0">Media</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">EVC Group</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">EVC Group</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Jenifer Kirtland, 415-568-9349</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Christopher Gale, 646-201-5431</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Douglas Sherk, 415-652-9100</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!1`,@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^Y7QFOQ%\
M-QG6O"07Q1I]NXGO/"E[&LVJ)$C#SI-$NP]O=W96`/)]BFN[NZ0C_B7V&LW(
MCTF]\OT+]JOP)%9?;O&FEZWX-TNWNWTZ]\60V=YXH^'^G:JDR13Z7KGB+2;%
M-:^'^K6T\L4%SHWQ8\,_#W6(YG\@Z>V-U?5[Q)(NUP2.?XCD94J<-G<I*DC<
MI##)PPKYY^+7P(M?&NHGQIX&\1W_`,*OBW:6\<%GX_\`#EO#+%K]E#$$M_#G
MQ.\/SJ=+^(WA(E2%TGQ`IN=,S]IT&_L+L/YO)B8XF/-5PU2;<8M_5TD^=I7M
M3NU[[MI>235VY(VIRIM*%2FHZJTJ=V[]I7LN75ZV;79WLO9/#OBWPOXPTN'7
M?"/B#0O%.B72>9:ZQX<U;3]=TJZC#%/,M]0TNYNK29=RL,QRD@JP8!E(&\)%
M)4@A@Q'S+@J,G:`6!V@\#`)!.,88\5^(^KZ-\+;'XCKX`^-.EZ[^PY^T5J,X
M/AWXR_L]^(=3\&?!CXN33NMM9ZC9K:RVMC%]OFE1=4T?Q!'87D<L3V^K^*K:
M:]AL9_6=>E_X*;?L_P`+W^@:C\/OVLO!$`5H);C1);/QR-/0A8I9-,TN]T/4
M+V_GC*S&;3-3\6Q2$O.MA"A->;1S=*\JN&?+&ZJU<-^^E1FFERXFFN6K3FM$
M^6$XZ-J32NNB6#@^14ZT:<FU95'RQEK&T8SCSP=]+7<.6ZYDMS]9Z:[A%+D$
MXQPH!8DD```D`DD@#D<U^+^C?\%?M.T/47T#XR_`'QKX-URRD6VU.#0-3M-0
MOK6[).8Y]`\2VGAF>U(0&1(3J]S<2*"$1C@GWW0/^"J'[)>N1JNH^)?&/A5V
M1,C7_`NK;0Q&7"RZ(VM)(\3#]ZL6YHF!^1E4FM:6?Y/5DX?7Z-.HE=TZJJ4Y
M+R]^"3?DFPJ99F%*S>$JSBVE&5-TZD9-VTCRS;=KWO:V]FVK'VC:^*H[CXQ^
M*?!@E)?2?AGX!\3>2%X4>(/%GQ&TGSBXR"!_PC8+KG*HJN`P:O3P274^H.<=
M.54\?E7XXZ!^V7\(;#]IKQA\?M5\77EK\#/&?AK4?@KX:\6+H'B5X[_7OAOH
M_P`+_'5N(],33'U:*/[9\0?'NFK)-IENQN+92G$WFO[+K_\`P57_`&3]'+C3
M=6\=>*I8UW`:!X-DMXY&PVV%9?$E_H,:N^#@N53@C>N,'..?97%57B,?0I1C
M.4Z:J-ING%IW22;DM+KE3W35]2Y9;CI3A&&%K5)*BN91BO=;2M%N3BHN]KIM
M6>[1^EQX!/IZ=:K.\?W6)&!T)'3G.<'CD@'<%P1SVK\8+W_@K=K'C;55\+_`
M3]F[Q=XS\1W:C^SK?5]1:[U!MTWV?S[CPUX2LM4E^QQRE/-NUUY;92ZHTZ,P
M->BZ1HG_``47^-=C-KOQ7^)/@G]DGX=^1)>:E9^$=+MI/&5IID<1N&NI;F]U
M+5YO#H$<;-JE[JOC339K/+R+IL<?F1J?V]@ZZ2P$*^82=G:A1:I1C=/GJU*S
MI0BDKM:MZ.T6*>68BE&^*=+#P>CC4K1=24ND8PI.I-R>J7NV3W:OK^E_BOQ[
MX(^'^FOK'C?Q7X;\'Z/$"#J?B;6],T2R9]K,L44NHW5N+B:14?RH(!++*R,D
M:EP%/@&M?M2^&[N31H_`WA;Q3XDCUZ:>W\.ZIJVD:KX3TGQ5<00_:9K?P9I&
MHZ5/X^\>O!"J32ZAX2\%:EX3L(7>?7_%F@6D-Q<Q?`/P[T;P%XW\=WF@?LH^
M'[S]H3Q]HEY';^./VT?VE+_4/B3X5^']R&C=SX$M-9EMT\0^)K4,USH=CX=@
MTNQAD&GRWM_JVAS2WT'ZB?";X,>'?AR;_6Y]5USQ[\1==M(;?Q9\4?&MRFI>
M,/$4<<TT\=E%*EM:V'ASPS:S.[:5X2\-66F^'M/C\MX[6YNO,U"YNAB,9C'*
M-.%/#4T]:]&3G3<TUSPISY8J516<9I0Y$KN%25K&4J=##I<T9>T22C3FN7FT
M2LUS.25G?5IZ)..NG1>#-/\`'5R+;6?&E[;V$\B;XO"^DQ0"WLUECRO]KWPN
M-3:YU&#>T<UO8:K>6$<R.W]JZTAMY8?2Z:%`P!P`,`#H/P_3Z4ZO6A#DBEN]
MY/\`FEU?SL<FEW:*BK[+;_@=OE<****L`HHHH`****`"BBB@`HHHH`****`"
MF,NX,,`Y'`/`)QCD@=#TS@X'8]*?12:OZ]&MUZ/I\NF@'C_QF^!_P[^/7@G4
MOA_\3-!MM=T+4$=[68%[;5M#U,1216NMZ'J$3>9I^JV;2LZ31`0W"&2TO[:[
ML;BZMY?QKD^)G[1O_!,SQUIG@7QXVH?&S]F?5;F6W\#ZM>D0ZAIEBB^;-8Z)
MK$L-W_PCVNZ1#%;2W'@R]G7PM?I;F;POI^C0S7FJ6?[Y'&5R/7D]O_UUYY\4
M/ACX'^+W@?Q!\/\`Q_HEOKWAGQ!:B"]M9@JSP3Q-YUCJ>FW01YM/U73+I8[S
M3M0MA]HL[J-)8PV"K>/C\M=:3Q&!G+`YA%\\*U!*$,3:UZ>+@E[.M"5N1.I&
M4H7O'K?KPV)5%2I5XJIA:CC[6+BI2C%-7G3D[RC):_"TG9)VW7B_AW5OV9?V
MT_`%MX@CT;P?\4O#;1K9RP>(-(M3XD\+7MVCB;3-02Y:/7O#>JHZ>2/L<D0F
MGBCNM+O+Q$6XB^2_B-_P2+_9[\3-/=?#G7O&'PLNYF,D5M%=R>,]!0E_,`-E
MX@NDU^1%Z(H\4(R[48LQ4AORM^(GA+XY?\$WOV@H[CPCXDO!I=Y$;_PEK\D,
MW_",?$GP;!/&T^A>+]+M7@MKR[L=L5KX@TO9'/IMUY6L:'J%G'>Z;<2?T*?L
MJ?M#Q?M,?"?1?B1'X9UKPG<RW$^CZMIVHV<\>E7.L:>FR^O/"^K3)LUS07F5
MQ:W4;)<6DT=Q8ZBGVJU#2^1@J^`SFI4P&98*FL?3D_:)044W3U<HU*?*X)VO
M925WJF[:=^(IXC`.&(P&+<L-.*E3GH[*5ERS@TUS6VNK^CL?&6J_\$O;?5/V
M<?`/P,3XH6=MKGA+XI:]X^U+Q\_A*ZO$U.S\0:9<:3>6%OX<?Q);O#=-9V?A
MH^;=:[=*DNF7`5]DL>.F^&__``2<_9K\&FWO/',OBCXKZHF%D77-2N/#N@RD
M)(50:-X7GL+N2%6"2^3J.MZA&[1!)O,B9D/Z@HP&X,1][@<Y^Z#_`"P??-?$
MO[;W[65S^RK\-['7-(\+7_B;Q5XLNKO2/"]U=V%T/!.BZA`D1-YXLU6*2V53
MY<IETO0K6XAO=:>WNRMQ:V,-Q<1^G/*LGPU-XRKA:4?JM%IRG>JH4Z:?V9-Q
MDVEHY)O;4Y:>-Q^(<:,:]3]_43:3Y.:4VKWE92Y7>_+?E5]%:QN_%+XL_LX?
ML0_#]9KG3?#?@RUO%<:!X`\#Z/I]KXC\77T,#!6M=,L3%+<0Q)'MOO$>K2FS
MT_`2>^,TT-M+^:G@VU_:(_X*?>*;C4_&]_JOPE_9-T#6!O\`"_AV4$^);JQF
M$BZ%::A+9VEQXMUS]U!_;7B#5;>?PSX<D9E\/:%:ZFAN+GY7_9F^`OQ0_;]^
M-6K>/_BWXCUS5/!FD7L$_P`1/&MW,T%S=RI-#<67P]\(IL:UTN[EAG6:*VTJ
M&'2?#&B^;=!5U=]*35?Z:_"OA3P]X*\/:/X3\*Z)9:!X;\/Z=;:5HNBZ=;);
MZ=IUA9H(XX+>!!L7'+RROF>YFDFFG9Y,N?,R^6)XA<:CYL#DM.=J6&HOV4L:
MX-)NJX*,_9*2LX<W+)2=TVKG56=#*=I0Q&9.G)3K3IJI]64^6SI*2:]H^E2R
M<;*2[//^'WP\\&_#+PIH_@OP#X>T[POX5T.`6^F:3IGF&"./<-]Q<3S/+=ZA
M?W)42W>I:A=7E_>3N\]W<33.[MU\TPM<94L7#E<,H^XN?FR=QSP/W:2,/O,H
M16=;"#"@<CJ<$D]23W)XYX`X`P!P!7PS_P`%+/B[X_\`@/\`L/?M%?%CX8_:
MX_&/A/P&'TR_TZ)Y-4T*'6O$GA[P]K'BG2V5T%OJ7A+P_JVL>)M.NY<P65_I
M5K?7"M#;.C_:X+!^VKX7`854Z/UBO0PM&*484H2K584H:)<L(\TH\UE9;V/!
MJUFJ<J]9SJR4>><IWG-R:3E)M^\Y-ZMMW;O=V/JC5OBM\--`U(Z-K_Q!\#:%
MK`>&,Z5K/B_P]I>IJ\YVQ1OI]_J%O>)+*P98HGA#R.K*HRIQVHO86`,;+)E4
MDRCHZB*56:&8LK$>3-M;RY1F,A6;=M5B/C?]E#XO_L>?'?X3>'T_9M\3?#/Q
M;X3O/#UD]_X1MKK1+WQE8;[:$7]K\2?#E^\_BA?%"S2,/$EYXIM)]2U'4IYK
M^[OM0>Z>[GK_``I_9*T'X%WG[5EO\-);+2?"WQ^O]/\`$OA3P2TMZNA>`-<C
M^&5MX'U?1="T[RV@T#P;>ZI96WB*ST+18TL=*O-9UFWT^QLK9K.SCZ<1A%AJ
MM?#8KZQ@<11J4X*EB,/*G4E>K&G+FC4Y7!M<TDN62:O:4?=<L85W4A3E3]G5
M4UK*-2+2E_+[NEUI?9I.]CZ^/B;000#K.CAF`95;5;%696&4909LE6&"K8PR
MD,I*\T-XFT!,"36M'B+H7C$FK:>F]0`25S<`E1GE@"H&&!(/'P+\$/V&/@5^
MR1^R=<?"WPI\/O!NH:WHGP@U*W\:>/M0\-:1J'BGQYXPL_!]P-9\2ZYK]Y8?
MVC??:]4\^72;:1X[?1K%(;"PMX+=-J_G)_P;Z?#GX?\`Q#_X)\>+[3Q]X%\'
M^.;74_C]\0-+U*W\8^&M&\41:CIQ\*>`@MC?)K=E?"[LU^TW`2VN#)"@GEVJ
MN]J[XY3A*N69MF=#&XB5'*L=@<(E4PM.'UNGCO;M5DU5DZ7L_8.,86DY\S;E
M#EUSGBJE.MA<-*DI5,32JUN:,KJ*HNFI)I)*[=16MV?J_P"B2UU&VO5WVLL%
MP@W*SV]Q%.B2(%+Q,\3,F]5DC;&[)61'`VNI-:_UW2]*>S35+ZQTXZCJ%OI.
MG"^OK6S.HZK=QO+::78"YDB^V:E<I#.]O86_F74T<+O%$X5]GR'^QE^R+X4_
M8QT;XZ>!?`&VS^&WQ$_:"\2_&+X?>'3<7-RW@O0O%?P_^%VB7W@X374:,++2
M/%/A+Q&_ARV22Y:U\*7.A6EQ=W6HVVH.OY??\%Q[OXWZA\+M%^,?P4UR^T[1
MOV%?C9\(/BQXLLK2$3KK/CS6!#<Z+J5PZW$,\%G\)]-UGP5JFI6Z1SP:OI'Q
M:U.ZO)+.V\-2QZEEE>64,RSC#Y=#&JEAL37]DL95IV5-RC%4J<J<9-?O*TH4
MOCDXRF_?:29IB,14PV&J5W0]K*#7[N,K-12BY23ZJ*;>UW:UDS^A%9`W\+#I
MSCCG\B".X(!'IS37FV!B48A2>G)('5@`"3T.`.21CJ:\,_9M^-WAS]H_X%_"
MGX\>$W0Z%\5/`WAWQ;%:I(DCZ1J6H62G6_#MVR2.5U/PUK::CH&J1[G6*\TZ
M2-9I&21J]=UC5=-T/2M4US5[Z#3M*T?3K[5=4O[I@D%CI^FVTU[?7<Y8C9!;
MVMM/-,Y.%2-R>`:\BK1Q.'J5*.(A[*O0K8BC4H2LFYTIN"@WO&4>5\R6K::O
MU.BG4IU(0JQ=X5*?M(-.ZDM-$_GW?1=5>:'7-+N;^^TJWOK*?5-+ALKG4],@
MO;2;4=/M]3^T_P!G7-[8Q3/=6MMJ!LKL6,]Q%%'>?9IS;-*L,C)H&=$0NY"*
M`"Q+#"Y]22`,?7IS7\RWA7XQ?%G]EG_@M#X?\1_&K5;R'X8_\%(_A3X0A\.6
MNIK/;V/P[O;<7%G\)?AY="6=((?$W@'5=-@\)>)GMO,L;RZ^+`U>*,++MM?Z
M8F$3J\#[7!!5HB00R@<JRG&\%.&5@5*DAAM.*]3.,HJ95]2FL0L1A\QR_"X[
M#8B$$H/VDU2Q-/LYTL1&K0Y7JW!-).22Y\)BEBEB+4W"I0J>SE3;]Y-\KA)]
M5&<9)J35M=-DWG?\)-H1&Y-7TET"EF=-4L2@`)`!<3E<D@@<XR",[A@KIOB7
M0]95WTC5--U6./[[Z7J%GJ2KAC&Y8V<TP`20&-CD[7^1]K!@O\W/_!0#PWX>
MTG_@M5_P2]TK3-`T72])U'3+>2^TNPTJQLM-OIO^$N\<$/>65O;Q6EU,H"E&
MFBDD4\J0>:]._P""ZOA[0_@W\$O@O^T!\$@?A?\`M3:)^T)X(\+?#+Q;\+K&
M+0/B%XRBU_1_$MUJ7@:>V\/1V=]XWT:[O-/TZ^;P]K$&I64MTITTVGDZ_>6N
MH>G2X<A6K<-X?Z\X2XER]XRC5='W,)+GQ,(QJMR2Y+X6JZM22Y:4/><&X23Y
M9YC*E3S"I.BI+!U)P24K<RM1E!KO93DK=797U5OW[O?$.C:6UHFJZGIVER7T
MQM[--1O[2Q:ZGRB^3:K=30O<REG1/+@620.RHRAF`HKY9B^#VM_'?X?_``"\
M6?&1=0\(?$O1_"/@;Q)XWT'1(-.-C8>-KWP@K>+]$C74K>_FMH+#7-:UW3HT
MW36LD*PK>Z9<S6&G7MN5X\</@XIQJXIQJQE.,XQI.<4XRY?=DI)2B[-IJ]U\
MK]RJ56DU15FDU>=G9I.VW35?\,C[`HHHKSS8,`]1FO/?'GQ'\*?#[3UNO$EW
M<QSWLCVNBZ+I.G:GKGBGQ+>QA6DL?#'AC1;2\US7KF-&66Z73;2:*QM?,O=2
MFLM.BEO$[Z3=P5SD;C@8PV!]TD\C/."._<=\>TT/3+/4;K58-/MTU.]2..\U
M-HA)J5S`CAHK:>_DWW#VELQ+0V8D^S1-EXD5R28DIOF49*-U9.UW%M;]G9ZI
M:?Y!^97QC^%_[1G[6=S97/B3X2>!/!'PY\$ZA+XB^'/@7XL^(5O=:UWQ';V%
MQ:Z1K?CC3_`LE[<K'>F]6VB\#GQ7X=TG3\AO$_\`PF-O(NEQ?`G[*G[8'Q\7
M]KCX9^#?BMXNO+/PG)KVM_"G5/AI8Z7I'A;PIX6O);34?#NC:;9>$_#]AIVF
M:5/X?\56VAZ>)+BWFN[:SANH1<'^T;F8_P!)'E1;@WEIN`(#;1N`8DL`W4`D
MDD9P22>O-?S8_P#!3CX8WGP2_:>\-?&OPG;1V5A\0IK/QW:M"'BMX/B+X&O]
M&36WE8(%0:A&FAZQ=%94EN;N]OI/F2W&WX[/<)6R^6$S6CB*]2I3QE&&*M&G
M",J-22CSS4%&+ITFN9J5]&TMG?Z#*ZM'%\^7XBG!1G1FZ$HI)PJ17-)W>K<D
MKNSO==K(_I(W_.1@#.<G<1DXQE25`*@%1G(!&<<K@_S%Z_\`M5?M%?&7]I'Q
MM\.O`7B&W\<>`_BG\3]2\(Z!\+/'6D:7XI^'EQX7CUI],TJ:YT_4+)+K1[2/
M1((?$]_J&DWNGZEITUD\UM=2W*Q,W]`GQF^(MGX;_9\^)OQ4TUF:VT[X1^)O
M&.C3?*))Y9?"=W?:*B'>JK+/<RVD:`2J3)(JH_4C\=_^"/\`\$5U?Q;X[^.V
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M"7VD:O:6.I64P\JXMD;)'5"*,8^1!C.W:H&T8"C'<':`"1C@8Z5E2:%I/]J'
M7(]-LXM9>*.VFU2&!8;ZYMH1((+:\N8/+FO+6#S93!;74DL$#2.T2*S-GZ##
MX-X6%.E3K2G3II*,9QA'EO;FY>1)-.VTDVM%S::^;7K/$3=6<8JI)MSE%6YM
MDFUM=6=VK7;O:[9KH0RJ0,`C(Y!X[$$$@@C!'/0UQGC;6?"6GVNDZ)XPGTO[
M'X[U;_A!M.TS6;=;O3O$6IZQINI7?_".W%O-!/:7`U73-+U2(6M^$L[T*UD[
M-)<112=HH"@`<`=,=/P'8>@'`Z"OE+]L/]G'6_VG_AGX>\!>&OBMK_P4\0>'
M/BA\/OBAHOQ%\+Z19ZUK^AZK\/-:&O::-+L]0N[2Q,UW>10VTS7ANK1K&2[A
MN;*YCFVCTJ$82JTU5J^P@Y+FK)2?LFM5-*-Y/EE9I)-^3V.:IS\DO9QYYZ6B
MVDI*ZNKO;W;_`*:GYV_&G_@@E^P]\1=4NO&?PMB^(7[,OCJ63[?9ZM\'?%MU
M'H.GZN7>>&^L?#'B4ZG;:-%!.T?DZ?X3U#PKIT<<4:P6ULZ12Q^+_L,>)_VT
M_P!D3_@H+>?\$\_VB?C#JW[2WPG\8_!W7/BU\(OB=XDDO)_$^D:/X;F>`W=P
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M(:\?\B%XN'``_P"8!J`Z#@?3L.*_$#_@W`/_`!@!XB']W]HWX@#Z_P#%+?#L
MY_6OVQ^(^B>-/$OAO5?#WA:X\.6$>N:)K.B:E>^((]7N7@BU73;JPCN-.BTR
M:W$DEL]PLTD=UY8FV&-&7(D'PQ_P3B_8>\??L`_!BZ^!Z_$7PC\3_#NI?$7Q
M%X^O?$`\,:[X5UVV?7](T'3#IUI9?VUK>GS"V.@PSK,\EI_Q]31K%^[3/-@,
M;AJ/#6<8"I42Q>*QN35*-.TW>G@XXSV\W.W(K.K3LF^:7-LK.^\Z%6>/PU=1
M_<T</B(2G=:SJNARI16MK0EKL?H/X[\3Z;X)\(^(/&&L"1M-\+Z3J&O7<4$8
MENKJ+3;2:X-C91DKYFH7[*ME81*ZO/>7$,"[S+Y;_+\/[/GQ!\6?!+QE\*?B
M-XE^%U]8_&#1?'B_%73;KX9>*=4GO-1^*O\`:=SXIL&UNT^,6E"_&A)K#:!H
M.K6]CIS6ND:-HL6DVVCVMA8VEIZM\3?!OQ+\9W^A66E:EX(@\':1XI\.>*+W
M2M9L?$D^IZ_)X;:ZU33]*O;NQNHK&UL[;Q9%X=U^*465X+A-!&G7UK<0WTLD
M/L.GQZB=(MTU?[&VKFT`OWLDG%@;TH?.:S6Y:6Y2S,NYK>.XDDG2`HDS-(&)
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M-O>1V.J"W7P]X?OHT:72K5$^]?"?@OXH6?Q*U;Q[XFOO`-_!KNE>'?#9L]-T
M[Q#;7F@>&O#T>LW\>GZ1+=7$]NUUJ7B+7]0U36+FY#)=00:1IQ5O[(L;J'W\
M^Q6`Q^8QS;!UH.IB\)AJ^.P[4TJ&;."CC.7FCR24Z]Z\)1=G&3C.TM_-RZE7
MIX:IAJL.54:U6&'DVFG0E-3IQ?*[Z1]QW6RTV1^2O_!;G]E;XG_&']D:]^+]
MEXC\*ZE\1?V6-5?XR^%[CP5\/O$WAWQ4/#5LMK9_$&"RU>]^*?B2U6/3-%@T
MSQV\!TF>_O)O`$%EILUJ]V]?I+^PC^TSI_[7W[*OP:^/EO\`9H]8\8^%S:>-
M;*WEA9=+^(7A2\NO"WCFR6*!(U@MSXBTN]O--C,4!ET>_P!-NXX3!<+)7TEX
MWTK4=:T2\TC3=.\-:G'JL$NFZMIOBVVO+G0]2T*^BEM=8TZYM[(%IC?64TEO
MY=S')9NKE9XY%.VOS(_X)Z_L`?%__@GUX9^*'P]\*_&/P;\1/AQXY\:IXX\*
M^%_$7A/Q+I$GP\OY+:YTO5;2QU6V\2:I)KL.KZ59^'(KRXN;33GDO=%?5&C:
MXU2YC6EF."QW"D\NQU50S3*,SI8K)X.FY+$Y;F%XYCA'*$6J?U?$TJ.-I>TY
M4YNLE>4E$MT*]#,E6HPO0Q>$A'$V=G[:A->RJ-/=<GN)+5-<S5M5\+_\%(;"
MVU3_`(+6_P#!+W3KO[4+:\T&VAG-EJ%_I=UL/B_QRW[N_P!+N+/4(&5E#*]O
M=PL#G)8$BOL'_@I[\.+C]G[]GSQ/^VG\!=<U3PM\?/V=%\.:WH&M^*KR_P#B
MGH.J^#=7\7Z#HGC/P;J'AOXH7_B[2]%L-:TK4WN)O$'@^W\/>*["XL8'L]:B
MB#H.O^/_`/P3^^)WQW_;-_9D_;"OOB?X%\.:M^S9:16MCX'L_"?B'4M/\5+'
MJ^MZL7O-<GU^SNM*+'6#;JL%A>;/(#Y=9WC3[>^-7P3MOVB_V?/B7\!_BO-:
M0Z?\5O`_B/P1K]_X02X0Z9'K5O-;:;K6AC63.W]IZ'.;/5+07WF0-J5C$9,6
M[.A[JV=8&_!7+6]K2RO+(X7-J2A)-4\3F>-JXK#I3BHU/:8'%5*4FKP;J-<V
MASQPE6K_`&I3=/DEB9.K0E)I)R]G24=5=IQG3NW]ER76S*7['?QRF_:7_9>^
M!GQZN])M=!U/XI?#O0/%.N:)8O/+8:3XCN;;[/XDTZPDNO\`2GL+/7;;48+)
MKEI)S:QP^;-,X:5RO*?V&/V<?C!^R5\#_`?[//BGX@^`_B-X)^&+^(]+\+>*
M]-\+^(?#7B[4?"FH:M>ZQX?TS6-)N/$.K:):ZIHUSJEY9W6I6-[=VE_IEK81
M6^F6EPDMTY7RN8K#1Q^-6"FJF#6+Q'U2:4ES8;VL_8-J24DW2Y.925T[IZGJ
M4'4="BZT>2K[*'M8MI\M3E7.KQTTE?;0^Z:***XS4****`"OS:_X*A_"V/X@
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M-?$0*&.X.N>-?^*BN([T,Q9[G3K2_LM'D+`E1I\2@X7G\P8=!U#QU^P3^QW\
M#;X.FJ^(?VM['X4>([/`:>"PTKQ=\5+O7A/&I+^3HMG$D]PZ*?+AM!*"`Z9_
M>V"".!88H(TC@@B6&)%``CCC1$BC4#HJHH4`<8`]*\S+:$9XR&+E*[HY;A<+
M2O\`9FXKVZCW;48<VKY;VM>39UXJ2IT?JT7;GQF)KU.5JSLHJE=[VM=+6TM;
MWV=JBBBOH3SPK+U0:DR0C3+FPMIMY,CZA97-]"8AMWA8[6_L)%D[JQE9">&4
M<&M2O'/CK/XD7X?W=GX-\4:+X2\7:GK'ABR\/:AXAU.?1-)U*\/B32KNZ\)3
M:[;6]S=Z'<^.-'M-4\'Z=K%C#+J>G:CKEK=:5;W.HQ6T+14ERPE+WO=3?NKF
MD[:V2L[M[;=>FXXJ[2.X\KQ>,9U7PN,^OA[5?;KCQ*1_GK2^3XP_Z"OA?_PG
MM5_^:6O(_@%XL;Q7X:\2><GC&SU;P_\`$#Q!X8\0Z#XVUJU\0ZAX0UK3;#2V
MU#PYI7BBQDNH/%^@6K75M>Z-K=S-)>26NJK::FT.KV=[9V^?+K^K6?[4K^&]
M0U_4;;PI=?`1/$6G:%=:F;71)_$EEXXN=-UK4[.V>2/SKVPT'^S3?!))H--@
MDAOO)@GNFN)^6%95(4:JYW[9M?O(V=./2332M%I;O2^F^U\EG;E2U5_=M_+?
M6]WZNUU?4]K,/C#_`*"WA<9Z?\4]JO\`7Q+1Y/C`?\Q;PN>_/A[5?Q_YF4<"
MN4^%4EXWP]\.7%[JFJZU/-%?73:GK=\U_J5Y9W.KZC+8S374JJTT8L!#]G(2
M-6MXX@I<Y8_%WQ%^)/CO0?B]\4]+L_&VO>&M)TWXI?`'0K'QCJ^L+/\`#;X9
M6?BOPSI.KZ[IWC+09K75-VC>.W:]\.Z1>7D%C86WBS7M$L9O%GA'[7::HKK5
MW1ITJD^>U5J-HQO*$FKI-)72:3O?9V3[CIT?:-J,DG&',^BM>$;:NUVVNG-T
M2U2/OWR?%_\`T%O"W_A/:K_\TM)Y7B\\?VMX6Y]/#^JY_#_BI:UKZ606<\MK
M`US-'%)+;0QR"(7,L<+R10B?:VU;AMD0E0,Z%PZ?,HQ\)^#/B'J=]\%_A1\7
M?%'C3QWJ_C?QC\1OA[H?BK3?#FOV6AV>A>*/%7Q*L/!T_P`,KKP+JHCT*QT#
MPQK<[>%O%ELMC_PL*UL-.U/4;[6;F\2\FDF=:%.2O.M>2BT^1V:?*E]E*^NV
M^KVM=Q&+E%R6R;5GU:_K\DM]/M7RO%P&#JWACWSX>U;/Y_\`"2'FE\GQ>`/^
M)MX7QV)\/:J?IDCQ)^M.\5&6/PYKS+<S6#_V+J[I?6MP;6>SDCL+B2*ZAN@5
M$$MN561)"RA2K2-\B,1YW\`-7OM?^!/PD\0ZQJM]KFK>(/ASX1UO5=6U*[-]
M=7^H:MH-G>W]Q/-O;,C7,\AEB7RUBYAPFW`T;I0J^S]I4YE1]M)I*UE**Y7:
M*7-=IZ^];JMF67*IW2U2<.JTWM?5:6;=KM^9Z#Y'C`G/]K>&1@8Q_P`(_JH'
M//;Q+U'^<T&#Q?QG5O#''`/_``CVK9_]27J>_%?+?@Z^UCXHZA^T+;^*_B)X
MH\!:WX1^(/BGP'H%AH?B=_#,O@7P;I^FV-MX-\<1:3=H-.URZ\6K>W7B6/7O
M$EIJFDW<AM=+TWR5TB\63[##QM912&:&=)(8C]HC95AN!(BXEC9'9?+FW!T*
MNR[6!#,.2X2A*//%M0FW)SE:Z5E!RYGLK+;1+>U[E.U[*S3LK*[Z1OUONM--
M7?8P##XOX/\`:_A@9'_0O:MS[X_X23@_3%!A\7@'_B;>&/P\/:J3V]?$I_0B
MOF/1_C#K\?QET&[UF\OX_A%\8UU3P=\.);O3([#0]-\6>$SJ6L>&=5T_7W<0
MZO#\:O#A\3ZMH[>9()8?#/A>WM8HIM37[5[G\;M4O]"^#'Q7UW2]0GTC5-$^
M&WCK6M,U:UF:VGTW4-(\+:MJ5AJ"7`^6)K.[M8;@-,KP-Y826.1&*F:=2$J<
MZL)2TFU.,TKNUDI6:ORRCK&VDK.PG#EY4U97\T[::<UT_6UNIVE@/$*3YU*]
MT:XM0"NRPTJ^M;DN?]6RM/J]^@0/O#EH5R`-K#DT5QGPN\3:??>!OAI::AK\
M.I>)M9\`>&];DCOM2@O==U4C0M)N-4UF1=_G7<:WE]&;S4((_L4=U=PP!XI)
MH825T4Y*5.$DK)Q326R5MEY=B7N[;=#U2BBBK$%%%%`!4,I"J[<97!Y.!@`<
MD]E!Y9OX5!/:IJ8V=AV]<\<XS\_3.&QD<=#2:33OV:]$]_\`AQ=O)IOS7;YG
MYG>`_`PM?CKX8\#M`AT[P+^U'^TO\5X("(_*L[/4_ASX/U714B.,1)#??&ZP
M,8^9R=PW9)Q^F2G@#'\.?UQ_/->':'X.&G_&3Q3XH\H(MUHTDRR;#'YC>(]/
M^&VCW)^4%79Q\,;=3M8LC*H/#AJ]S`P,#H.!7'A:4*3DHJ[;>MK)6M%I7OV6
MNFSWN:U*GM'S-6=K/6]VM&]EJ_738****[3,*R]7T;2==M38:WI]EJVGL4DD
MT_4K2VO[&9X98YH9)[2[BFMYG@EB26`R1L(I0LR`2QQNFI12:NK=[7]+JZZ[
MJZ!:?\#0QM,T32=&M8K32=/LM+LH7=HK'3;.UT^QC:1I))"MI9P0P*9)9I9I
M"L>9)9#(Y9PI6OK?AGPSXD-JWB#0M&US["97LEUC2K#5%M))E"RR6HO[6X%O
M)*$02M#L,HCC$F\1IMZ&BI]G#7W=.B[+2Z[/5-[:7\M5+F;TE9>>K3NM4].E
M_P`"O';10Q)#"HBBBC$44<2I&D42IY:QQ(JA8HT4*$2,*J!0J!5RIPY_"GAF
M9]7>?0-#F?Q`B)KS3:/ILC:W''''!''K#M:,VJ1QP0Q0(M^;C;%%%&/E1<=)
M15-)JS2=FFKJ^JV?J4G*.L79[7*<=I%#%';0QQPP1(L<,$*)'%#"BJBQQ1HJ
MI'&BJH6-5"8!&.!6$O@OPDFL-X@_X1CPX=>DG2YDUMM$TMM9DGB54BE?5#9_
M;FDACCB2&1KCS(TAA16"1A:ZFBIDI223<-+7]Q6LFM$KV6B[/I9*P7=K7=NW
M37<JWEK;7T,EK>00W-M-%)'/;W$4<\$T,J-'+#+%*KQR1RQLR2(ZE71F1@RL
M14-CI6G:;96^GZ796NF:?:Q)#:6.G6UO96EK"N-L5O;6T4<,,8``"1HJKCY0
MN!6A125**<I/WI2NKM6M#2T=.B:O^B$<S>>#/"6I:C;ZQJ/AKP_J.L6D<,%K
MJ]_HFE7FIVT-NQD@@M[ZXLY+F"&*1WEBCAD1(Y)'DC"NS$]!-!'/`]O(`\4D
M9BD5\.LD;+M=)%<,LBNI*NDBLC@D.K`D5-15**C'EBDDKV5KI==NJOT#8YL^
M$O#K6>F:<VAZ.^GZ(UFVB6+Z7I[V6BG33'_9G]D6C6IMM,_LM(HHM.-E%`;.
M..,0%&16&S?6%EJ=I/8:C:V]]8W43P75G=P0W5K=02HR2P7%O.DD,T,J,4DB
MD1DD0E'5D9E-NBERMIQGRN+W2CRWVW=_+YWN-MO=W.8TGP9X3T*[:_T3PWH.
MCWSP-:27FE:)I6FW<EF7AD^Q27-C9V\[6@EMK>0VYD\IG@A+JPC0`KIZ*I)1
M2BE9)))=DE9+[A!1113`****`"D'3\6_F:**`,L_\AD_]@Z+_P!*I:U:**Y:
M'Q2_[>_*F`4445U`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!_
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
